Targovax: Encouraging interim results of ONCOS-102

Our portfolio company Targovax has released interim results from the phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma.

Dr. Magnus Jäderberg, CMO of Targovax, said in a press release from the company:

“Given the limited number of patients who have completed the study to date, it is encouraging to already see a complete response to ONCOS-102 primed KEYTRUDA® treatment in this CPI refractory patient population. This case is particularly interesting, as the patient became refractory to KEYTRUDA® before entering our trial. At the same time, five patients progressed, which we believe may be partly due to an insufficient number of ONCOS-102 injections. Consequently, we have agreed with the investigators to expand the trial with additional patients, who will receive an increased number of ONCOS-102 injections. The complete response, combined with the optimized dosing regimen, makes us optimistic that we may demonstrate the full potential of ONCOS-102 in the checkpoint inhibitor refractory setting.”